Biotech Values

[iwfal]

I don't expect gene therapy for AMD to gain much traction for the reasons you mentioned and, more fundamentally, because AMD is the kind of multifactorial disease that is inherently challenging for gene therapy.

While i agree generally that multifactored diseases arent generally good targets for gene therapy, this particular treatment is a kind of cheat in that its using gene therapy to mimic existing treatment:

ABBV-RGX-314 consists of the NAV® AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).